Funding Opportunity RFA-HG-21-026 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity is to solicit applications for the Non-Human Developmental Genotype-Tissue Expression (NHP dGTEx) Research Center. The NHP dGTEx research center will perform four major functions: 1) create a tissue resource of multiple reference tissues across developmental stages in non-human primates (NHPs); 2) perform transcriptome sequencing and other genomic analysis of bulk tissues and single-cell populations; 3) perform analysis of gene expression patterns in NHPs and compare them to human gene expression patterns; and 4) make the tissue samples and data available and usable to the community.)

Funding Opportunity PAR-21-257 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) hereby notifies the applicant community that funds may be available to provide Personal Protective Equipment (PPE) to directly support the needs of the NIH Clinical Trials and Clinical Research Activities. Only applications submitted in response to a Notice of Special Interest (NOSI) published by an IC will be allowed to apply to this FOA.

Competitive with benefits, subject to skills and experience: The Francis Crick Institute: The lab is studying signalling pathways that control the biology of B and T lymphocytes. London (Greater) (GB)

Competitive with benefits, subject to skills and experience: The Francis Crick Institute: The lab is studying signalling pathways that control the biology of B and T lymphocytes. London (Greater) (GB)

Notice NOT-HL-21-010 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-21-016 from the NIH Guide for Grants and Contracts. This initiative will support the development of tools and experimental platforms for the purification and characterization of Extracellular Vesicles (EV) originating from the human pancreatic islet and its broader tissue environment in healthy individuals, and individuals with T1D or at-risk of developing the disease. It will also support the exploration of the contribution of pancreatic EV biology to islet function, dysfunction and T1D disease initiation; the development of EV-based diagnostic tools for disease monitoring and classification; and the use of pancreatic EV biology to identify novel therapeutic targets.

Genus’ RD is a growing organization with focus on industry-leading science and technology to support customers’ needs across our global business.
From IntelliGen Technologies - Thu, 03 Jun 2021 07:29:49 GMT - View all DeForest, WI jobs

Grad schools need to see beyond standardized tests, this researcher argues

Funding Opportunity RFA-AA-21-014 from the NIH Guide for Grants and Contracts. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) seeks applications to continue the previously funded Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD). Responsive applications are expected to address urgent and important unmet needs in the fetal alcohol spectrum disorders (FASD) field through an integrated and multidisciplinary research approach. These unmet needs include identifying FASD cases early and accurately, improving interventions to mitigate FASD outcomes; expanding basic and mechanistic understanding of alcohol teratogenesis aimed at accelerated translation, and reducing prenatal alcohol exposure and the incidence of FASD. Cooperative Agreement (UH2) applications in response to this FOA should propose exploratory/developmental projects of the CIFASD consortium.

Funding Opportunity RFA-AA-21-013 from the NIH Guide for Grants and Contracts. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) seeks applications to continue the previously funded Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD). Responsive applications are expected to address urgent and important unmet needs in the fetal alcohol spectrum disorders (FASD) field through an integrated and multidisciplinary research approach. These unmet needs include identifying FASD cases early and accurately, improving interventions to mitigate FASD outcomes; expanding basic and mechanistic understanding of alcohol teratogenesis aimed at accelerated translation, and reducing prenatal alcohol exposure and the incidence of FASD. Cooperative Agreement (U24) applications in response to this FOA should propose the Data Coordination Core (U24) component of the CIFASD consortium.

Funding Opportunity RFA-AA-21-012 from the NIH Guide for Grants and Contracts. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) seeks applications to continue the previously funded Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD). Responsive applications are expected to address urgent and important unmet needs in the fetal alcohol spectrum disorders (FASD) field through an integrated and multidisciplinary research approach. These unmet needs include identifying FASD cases early and accurately, improving interventions to mitigate FASD outcomes; expanding basic and mechanistic understanding of alcohol teratogenesis aimed at accelerated translation, and reducing prenatal alcohol exposure and the incidence of FASD. Cooperative Agreement (U24) applications in response to this FOA should propose the Diagnostic-Telemedicine Core (U24) component of the CIFASD consortium.

Funding Opportunity RFA-AA-21-011 from the NIH Guide for Grants and Contracts. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) seeks applications to continue the previously funded Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD). Responsive applications are expected to address urgent and important unmet needs in the fetal alcohol spectrum disorders (FASD) field through an integrated and multidisciplinary research approach. These unmet needs include identifying FASD cases early and accurately, improving interventions to mitigate FASD outcomes; expanding basic and mechanistic understanding of alcohol teratogenesis aimed at accelerated translation, and reducing prenatal alcohol exposure and the incidence of FASD. Cooperative Agreement (U24) applications in response to this FOA should propose the Administrative Resource (U24) component of the CIFASD consortium.

Funding Opportunity RFA-AA-21-010 from the NIH Guide for Grants and Contracts. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) seeks applications to continue the previously funded Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD). Responsive applications are expected to address urgent and important unmet needs in the fetal alcohol spectrum disorders (FASD) field through an integrated and multidisciplinary research approach. These unmet needs include identifying FASD cases early and accurately, improving interventions to mitigate FASD outcomes; expanding basic and mechanistic understanding of alcohol teratogenesis aimed at accelerated translation, and reducing prenatal alcohol exposure and the incidence of FASD. Cooperative Agreement (U01) applications in response to this FOA should propose individual clinical or basic research projects.

Notice NOT-AR-22-003 from the NIH Guide for Grants and Contracts

Conacyt faces at least 145 wrongful termination lawsuits

£37,865 to £45,817: Wellcome Sanger Institute: The Opportunity We have an exciting opportunity for a Senior Software Developer with Bioinformatics experience to join the Sequencing Informatics G... Hinxton, Cambridgeshire

Notice NOT-HD-21-039 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-21-035 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for Biomarker Characterization Centers (BCCs), one of the three scientific units of the Early Detection Research Network (EDRN). The EDRN is a national infrastructure to discover, develop, and validate biomarkers and imaging methods for early cancer detection and risk assessment. BCCs will (1) discover, develop, characterize and test new biomarkers or refine existing biomarkers, (2) develop, refine and/or standardize biomarker assays, (3) provide resources and support for the validation of biomarkers developed by the EDRN, and (4) participate in collaborative projects with other laboratories and centers. The other two scientific units of the continuing EDRN program are the Clinical Validation Centers (CVCs), which will conduct clinical research on the validation of biomarkers and will serve as resource centers for the Network by participating in collaborative biomarker validation studies with EDRN BCCs; and the Data Management and Coordinating Center (DMCC), which will support statistical and computational analyses, informatics infrastructure, study design, coordination and management of EDRN-sponsored biomarker validation studies, and the coordination of Network-wide meetings and workshops.

Funding Opportunity RFA-CA-21-034 from the NIH Guide for Grants and Contracts. The objectives of the Early Detection Research Network (EDRN; edrn.cancer.gov) are to discover, develop and validate biomarkers and imaging methods to detect early stage cancers and to translate these into clinical tests. The EDRN provides an infrastructure that is essential for this process and has successfully completed more than10 multicenter validation studies.

Funding Opportunity RFA-CA-21-033 from the NIH Guide for Grants and Contracts. The objectives of the Early Detection Research Network (EDRN; edrn.cancer.gov) are to discover, develop and validate biomarkers and imaging methods to detect early stage cancers and to translate these into clinical tests. The EDRN provides an infrastructure that is essential for this process and has successfully completed more than10 multicenter validation studies.